As per a recent study, Ibandronate could prove as an effective treatment for relieving pain and is also safe to use by patients with breast cancer with metastatic bone disease (MBD).
The study conducted by Marcus Schmidt, MD, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, and colleagues analyzed impact of ibandronate on patients with breast cancer and MBD and suffering from severe pain, using analgesic and also estimated creatinine clearance in them.
There were involved more than 3,500 patients in the study and they were given ibandronate 6 mg IV for three to four weeks or they were put on a daily 50 mg dose of ibandronate. It was found that the problem of severe pain was reduced in around 64% of the total participants.
Dr. Schmidt said, "The data suggest that the analgesic efficacy and renal safety profile of IV and oral formulations of ibandronate seen in phase 3 trials transfers to routine clinical practice under real-life conditions".
Also, treatment with ibandronate made patients to depend less on analgesis and at the end of the study, 57% of the patients shunned using analgesic as compared to 54% who were at the baseline. The renal function was also found to be stable and no affects were casted by ibandronate treatment on them. There were only 7% cases of skeletal-related events (SREs) and the drug was considered as tolerated.
- J. Michael Pearson, Valeant’s Chief Executive Officer Spent Christmas in Hospital for ‘Severe’ Pneumonia
- Eversource Faces Stiff Challenge from ‘Society for the Protection of New Hampshire Forests’ over Burying Power Lines
- Shaw Communications Agree to Buy Wind Mobile for C$1.6 Billion
- Supporters of The Export-Import Bank in Congress make an Attempt to Revive It